<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01122797</url>
  </required_header>
  <id_info>
    <org_study_id>ET-PNPLA3</org_study_id>
    <nct_id>NCT01122797</nct_id>
  </id_info>
  <brief_title>Influence of Adiponutrin in Chronic Liver Disease</brief_title>
  <official_title>Study of Metabolism Influence in Human Alcoholic Liver Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasme University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Erasme University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Increasing evidence attests the influence of multiple metabolic genetic risk factors in the
      progression of alcoholic liver disease. Deleterious pathways involved in metabolism such as
      lipid peroxidation and cytokines have been implicated in promoting inflammation leading to
      fibrosis increase and liver injury progression. The aim of this study was to assess the role
      of rs738409 single nucleotide polymorphism in the PNPLA3 gene in alcoholic liver disease
      patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of fibrosis and steatosis by liver biopsy in alcoholic liver disease patients.</measure>
    <description>After liver histology assessment for liver liver dammage a potential correlation of fibrosis and steatosis was studied with rs738409 PNPLA3 polymorphism</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">658</enrollment>
  <condition>Alcoholic Liver Disease</condition>
  <arm_group>
    <arm_group_label>Alcoholic liver disease</arm_group_label>
    <description>Alcoholic liver disease patients undergoing a transjugular liver biopsy in our institution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <description>Healthy controls patients recruited from the Occupational Medicine Department during a routine physical examination.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      DNA extraction from whole blood sample. Piece of liver tissue in the alcoholic liver disease
      group.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Consecutive patients undergoing transjugular liver biopsy for alcoholic liver disease will
        be included in the study to determine the potential correlation between rs738409 PNPLA3
        polymorphism and/or PNPLA3 mRNA expression.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        ALD patients:

        Inclusion Criteria:

          -  Excess alcohol intake

          -  Abnormal alanine aminotransferase (ALT) and aspartate aminotransferase (AST) or a
             suspicion of cirrhosis related to ALD

          -  Caucasian ethnicity

        Exclusion Criteria:

          -  Presence of any other chronic liver disease

          -  Co-infection with human immunodeficiency virus

        Controls:

        Inclusion Criteria:

          -  Caucasian ethnicity

        Exclusion Criteria:

          -  Presence of a disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hopital Erasme- Dpt of Gastroenterology</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <reference>
    <citation>Tian C, Stokowski RP, Kershenobich D, Ballinger DG, Hinds DA. Variant in PNPLA3 is associated with alcoholic liver disease. Nat Genet. 2010 Jan;42(1):21-3. doi: 10.1038/ng.488. Epub 2009 Nov 29.</citation>
    <PMID>19946271</PMID>
  </reference>
  <reference>
    <citation>Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, Boerwinkle E, Cohen JC, Hobbs HH. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008 Dec;40(12):1461-5. doi: 10.1038/ng.257. Epub 2008 Sep 25.</citation>
    <PMID>18820647</PMID>
  </reference>
  <reference>
    <citation>Yuan X, Waterworth D, Perry JR, Lim N, Song K, Chambers JC, Zhang W, Vollenweider P, Stirnadel H, Johnson T, Bergmann S, Beckmann ND, Li Y, Ferrucci L, Melzer D, Hernandez D, Singleton A, Scott J, Elliott P, Waeber G, Cardon L, Frayling TM, Kooner JS, Mooser V. Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes. Am J Hum Genet. 2008 Oct;83(4):520-8. doi: 10.1016/j.ajhg.2008.09.012.</citation>
    <PMID>18940312</PMID>
  </reference>
  <reference>
    <citation>Huang Y, He S, Li JZ, Seo YK, Osborne TF, Cohen JC, Hobbs HH. A feed-forward loop amplifies nutritional regulation of PNPLA3. Proc Natl Acad Sci U S A. 2010 Apr 27;107(17):7892-7. doi: 10.1073/pnas.1003585107. Epub 2010 Apr 12.</citation>
    <PMID>20385813</PMID>
  </reference>
  <reference>
    <citation>He S, McPhaul C, Li JZ, Garuti R, Kinch L, Grishin NV, Cohen JC, Hobbs HH. A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J Biol Chem. 2010 Feb 26;285(9):6706-15. doi: 10.1074/jbc.M109.064501. Epub 2009 Dec 23.</citation>
    <PMID>20034933</PMID>
  </reference>
  <reference>
    <citation>Kotronen A, Peltonen M, Hakkarainen A, Sevastianova K, Bergholm R, Johansson LM, Lundbom N, Rissanen A, Ridderstråle M, Groop L, Orho-Melander M, Yki-Järvinen H. Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology. 2009 Sep;137(3):865-72. doi: 10.1053/j.gastro.2009.06.005. Epub 2009 Jun 12.</citation>
    <PMID>19524579</PMID>
  </reference>
  <reference>
    <citation>Kotronen A, Johansson LE, Johansson LM, Roos C, Westerbacka J, Hamsten A, Bergholm R, Arkkila P, Arola J, Kiviluoto T, Fisher RM, Ehrenborg E, Orho-Melander M, Ridderstråle M, Groop L, Yki-Järvinen H. A common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans. Diabetologia. 2009 Jun;52(6):1056-60. doi: 10.1007/s00125-009-1285-z. Epub 2009 Feb 18.</citation>
    <PMID>19224197</PMID>
  </reference>
  <reference>
    <citation>Valenti L, Al-Serri A, Daly AK, Galmozzi E, Rametta R, Dongiovanni P, Nobili V, Mozzi E, Roviaro G, Vanni E, Bugianesi E, Maggioni M, Fracanzani AL, Fargion S, Day CP. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology. 2010 Apr;51(4):1209-17. doi: 10.1002/hep.23622.</citation>
    <PMID>20373368</PMID>
  </reference>
  <verification_date>December 2002</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2010</study_first_submitted>
  <study_first_submitted_qc>May 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2010</study_first_posted>
  <last_update_submitted>May 11, 2010</last_update_submitted>
  <last_update_submitted_qc>May 11, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 13, 2010</last_update_posted>
  <responsible_party>
    <name_title>Eric Trépo, MD</name_title>
    <organization>Erasme University Hospital (Olivier Le Moine, MD, PhD)</organization>
  </responsible_party>
  <keyword>PNPLA3</keyword>
  <keyword>fibrosis</keyword>
  <keyword>cirrhosis</keyword>
  <keyword>alcoholic liver disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Liver Diseases, Alcoholic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

